SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Hepatitis B fact sheet. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 12 September 2007.
  • 2
    Yao GB. Treatment of chronic hepatitis B in China. J Gastroenterol Hepatol 2000; 15( Suppl): E61E66.
  • 3
    Guan Z, Dong Z, Wang Q, Cao D, Fang Y, Liu H, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004; 38( Suppl): S175S178.
  • 4
    Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol 2005; 34: 132137.
  • 5
    Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 11291133.
  • 6
    Kim WR, Veenstra D, Iloeje UH. The natural history of chronic hepatitis B infection: a new computer simulation model to incorporate events subsequent to HBeAg seroconversion [Abstract]. Gastroenterology 2005; 128( Suppl 2): A692.
  • 7
    Lesmana LA, Leung NW, Mahachai V, Phiet PH, Suh DJ, Yao G, et al. Hepatitis B: overview of the burden of disease in the Asia-Pacific region. Liver Int 2006; 26( Suppl 2): 310.
  • 8
    Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus—large-scale analysis using a new genotyping method. J Infect Dis 1997; 175: 12851293.
  • 9
    Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005; 12: 111124.
  • 10
    Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. HEPATOLOGY 2002; 35: 12741276.
  • 11
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678686.
  • 12
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 13
    Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. HEPATOLOGY 2003; 37: 13091319.
  • 14
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 15211531.
  • 15
    Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001; 12( Suppl 1): 119129.
  • 16
    Bridges EG. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity [Abstract]. J Hepatol 2006; 44( Suppl 2): S147.
  • 17
    Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. HEPATOLOGY 2004; 40: 719726.
  • 18
    Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528536.
  • 19
    Lai CL, Gane E, Liaw Y-F, Thongsawat S, Wang Y, Chen Y, et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial [Abstract]. HEPATOLOGY 2005; 42( Suppl 1): 748A.
  • 20
    Zhou XJ, Lim SG, Lloyd D, Chao GC, Brown NA, Lai C-L. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 2006; 50: 874879.
  • 21
    Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical evaluation of medicinal products intended for treatment of hepatitis B. Available at: http://www.emea.europa.eu/pdfs/human/ewp/617203en.pdf. Accessed September 2007.
  • 22
    Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679693.
  • 23
    Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007; 45: 507539.
  • 24
    Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26: 130141.
  • 25
    Standring DN, Seifer M, Patty A, Chapron C, Van Doorn LJ, Chao GC, et al. HBV resistance determination from the telbivudine GLOBE registration trial [Abstract]. J Hepatol 2006; 44( Suppl 2): S191.
  • 26
    Chang TT, Gish RG, De MR, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 10011010.
  • 27
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 10111020.
  • 28
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al., for the Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 6168.
  • 29
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 12561263.
  • 30
    Bzowej N, Chan HLY, Lai CL, Cho M, Moon YM, Chao YC, et al. A randomized trial of telbivudine (LdT) vs. adefovir for HBeAg-positive chronic hepatitis B: final week 52 results [Abstract]. HEPATOLOGY 2008; 44( Suppl 1): 563A.
  • 31
    Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother 2007; 60: 201205.
  • 32
    Yao GB, Zhu M, Wang YM, Xu DZ, Tan DM, Chen CW, et al. A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B [in Chinese]. Zhonghua Nei Ke Za Zhi 2006; 45: 891895.
  • 33
    Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. HEPATOLOGY 2001; 34: 139145.
  • 34
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 26822695.
  • 35
    Lai CL, Gane E, Hsu CW, Thongsawat S, Wang Y, Chen Y, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine [Abstract]. HEPATOLOGY 2006; 44( Suppl 1): 230A.